NKTR — Nektar Therapeutics Stock Price, Chart & AI Report

Negative Apr 17, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Nektar Therapeutics alleging that company defendants made materially false and misleading statements regarding the REZOLVE-AA trial. The complaint claims enrollment in the trial did not follow applicable protocol standards and that the trial's integrity and prospects were overstated. Investors who purchased Nektar securities between February 26, 2025 and December 25, 2025 are encouraged to join the case, with a lead plaintiff deadline of May 5, 2026.

NKTR class action lawsuit securities fraud REZOLVE-AA trial investor harm false statements protocol violations

Sentiment note

The company is the subject of a securities fraud class action lawsuit alleging material misstatements about trial enrollment procedures and integrity, which directly harms investor confidence and shareholder value.

Negative Apr 16, 2026 • 03:02 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, A LEADING NATIONAL FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against Nektar Therapeutics (NKTR) on behalf of investors who purchased securities between February 26, 2025 and December 15, 2025. The lawsuit alleges that defendants made false and misleading statements regarding enrollment protocols in the REZOLVE-AA trial, which allegedly overstated the trial's integrity and prospects. The lead plaintiff deadline is May 5, 2026.

NKTR securities class action REZOLVE-AA trial enrollment protocol violations lead plaintiff deadline investor damages

Sentiment note

The company is accused of making false and misleading statements about clinical trial enrollment procedures and overstating trial integrity and prospects, which resulted in investor damages when the true details became public.

Negative Apr 16, 2026 • 01:05 UTC GlobeNewswire Inc. • Law Offices Of Howard G. Smith

DEADLINE ALERT for EOSE, SLNO, NKTR, DRVN: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Eos Energy Enterprises, Soleno Therapeutics, Nektar Therapeutics, and Driven Brands Holdings Inc. The lawsuits allege that these companies made false or misleading statements regarding their operations, financial reporting, and business prospects. Lead plaintiff deadlines range from May 5-8, 2026.

EOSE SLNO NKTR DRVN securities fraud class action lawsuit false statements misleading disclosures

Sentiment note

Alleged non-compliance with trial protocols in REZOLVE-AA trial enrollment, raising concerns about trial integrity and overstated prospects.

Negative Apr 13, 2026 • 01:01 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, A LEADING AND RANKED FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR

Rosen Law Firm is reminding investors who purchased Nektar Therapeutics securities between February 26, 2025 and December 15, 2025 of the May 5, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Nektar made false and misleading statements regarding enrollment protocols in the REZOLVE-AA trial, which allegedly overstated the trial's integrity and prospects, causing investor damages when the true details became public.

NKTR securities class action lead plaintiff deadline REZOLVE-AA trial false statements investor damages clinical trial protocol

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misstatements and protocol violations in a clinical trial (REZOLVE-AA), which resulted in overstated trial prospects and investor damages. This represents significant legal and reputational risk.

Negative Apr 10, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Nektar Therapeutics alleging that company executives made materially false and misleading statements regarding the REZOLVE-AA trial. The complaint claims that enrollment in the trial did not follow applicable protocol standards, which likely negatively impacted trial results and overstated the trial's integrity and prospects. Investors who purchased Nektar securities between February 26, 2025 and December 25, 2025 are encouraged to join the case, with a lead plaintiff deadline of May 5, 2026.

NKTR class action lawsuit securities fraud REZOLVE-AA trial investor harm false statements clinical trial protocol

Sentiment note

The company is the subject of a securities fraud class action lawsuit alleging material misstatements about clinical trial enrollment procedures and integrity. These allegations suggest potential regulatory violations and loss of investor confidence.

Negative Apr 8, 2026 • 16:00 UTC GlobeNewswire Inc. • Glancy Prongay Wolke & Rotter Llp

Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Nektar Therapeutics faces a securities fraud class action lawsuit after its Phase 2b REZOLVE-AA trial for alopecia areata treatment failed to reach statistical significance due to enrollment protocol violations. The company's stock fell 7.8% on December 16, 2025, following the announcement. Investors who purchased NKTR securities between February 26, 2025 and December 15, 2025 have until May 5, 2026 to file a lead plaintiff motion.

NKTR securities fraud class action lawsuit clinical trial failure enrollment protocol violations stock price decline alopecia areata treatment

Sentiment note

The company is facing securities fraud allegations for making materially false statements about its REZOLVE-AA trial. The trial failed to reach statistical significance due to enrollment protocol violations, and the stock declined 7.8% upon announcement. Defendants are accused of overstating trial integrity and prospects while failing to disclose material adverse facts.

Negative Apr 7, 2026 • 19:45 UTC GlobeNewswire Inc. • Pomerantz Llp

Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR

Pomerantz LLP has filed a class action lawsuit against Nektar Therapeutics and certain officers for alleged securities fraud. The lawsuit claims Nektar made false statements about enrollment procedures in its REZOLVE-AA clinical trial for rezpegaldesleukin. The trial failed to reach statistical significance due to four ineligible patients being included, causing Nektar's stock to drop 7.77% on December 16, 2025.

NKTR class action lawsuit securities fraud clinical trial failure REZOLVE-AA trial rezpegaldesleukin alopecia areata enrollment violations

Sentiment note

The company faces a class action lawsuit alleging material misstatements about clinical trial enrollment procedures. The REZOLVE-AA trial failed to meet statistical significance, and the stock declined 7.77% following the disclosure of enrollment violations involving ineligible patients.

Negative Apr 6, 2026 • 22:35 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against Nektar Therapeutics on behalf of investors who purchased securities between February 26, 2025 and December 15, 2025. The lawsuit alleges that defendants made false and misleading statements regarding enrollment protocols in the REZOLVE-AA trial, which allegedly overstated the trial's integrity and prospects. The lead plaintiff deadline is May 5, 2026.

NKTR securities class action Nektar Therapeutics REZOLVE-AA trial false statements lead plaintiff investor damages

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misstatements and omissions regarding clinical trial enrollment protocols and integrity. Investors claim to have suffered damages as a result of these alleged false statements.

Negative Apr 6, 2026 • 20:52 UTC GlobeNewswire Inc. • Holzer & Holzer, Llc

Holzer & Holzer, LLC Reminds Investors of Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Aquestive Therapeutics, Inc. (AQST), Nektar Therapeutics (NKTR), and Eos Energy Enterprises, Inc. (EOSE)

Law firm Holzer & Holzer announces lead plaintiff deadlines for multiple shareholder class action lawsuits against pharmaceutical and energy companies. Aquestive Therapeutics faces allegations regarding false statements about its Anaphylm drug application, Nektar Therapeutics regarding its REZOLVE-AA trial, and Eos Energy Enterprises regarding production capacity guidance. Investors who suffered losses during the specified periods are encouraged to seek lead plaintiff status.

AQST NKTR EOSE shareholder class action lead plaintiff deadline securities litigation materially false statements investor losses

Sentiment note

Company is defendant in class action lawsuit alleging false statements regarding REZOLVE-AA trial results, suggesting potential misrepresentation of clinical trial data that harmed shareholders.

Negative Apr 3, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Nektar Therapeutics alleging that company executives made materially false and misleading statements regarding the REZOLVE-AA trial. The complaint claims that enrollment in the trial did not follow applicable protocol standards, which likely negatively impacted trial results and overstated the trial's integrity and prospects. Investors who purchased Nektar securities between February 26, 2025 and December 25, 2025 are encouraged to join the case, with a lead plaintiff deadline of May 5, 2026.

NKTR class action lawsuit securities fraud REZOLVE-AA trial investor harm clinical trial protocol violations misleading statements

Sentiment note

The company is the subject of a securities fraud class action lawsuit alleging material misstatements and non-disclosure regarding clinical trial enrollment protocol violations that allegedly compromised trial integrity and results.

Negative Apr 3, 2026 • 14:55 UTC GlobeNewswire Inc. • The Schall Law Firm

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors who purchased Nektar Therapeutics securities between February 26, 2025 and December 15, 2025 to join a class action lawsuit alleging securities fraud. The complaint claims Nektar made false and misleading statements regarding its REZOLVE-AA trial, including improper patient enrollment that failed to follow protocol standards and overstated trial integrity.

NKTR securities fraud class action lawsuit Nektar Therapeutics REZOLVE-AA trial rezpegaldesleukin patient enrollment Securities Exchange Act

Sentiment note

The company is accused of making false and misleading statements about its clinical trial, specifically regarding improper patient enrollment procedures and overstated trial integrity. These allegations of securities fraud and material misstatements resulted in investor losses.

Negative Mar 31, 2026 • 18:50 UTC GlobeNewswire Inc. • Robbins Llp

NKTR Stockholders Have Rights – If You Lost Money Investing in Nektar Therapeutics Contact Robbins LLP for Information About Recovering Your Losses

Robbins LLP filed a class action lawsuit against Nektar Therapeutics on behalf of investors who purchased securities between February 26, 2025 and December 15, 2025. The complaint alleges that Nektar failed to disclose enrollment protocol violations in its REZOLVE-AA trial, which overstated the trial's prospects. When the company announced the trial failed to reach statistical significance on December 16, 2025, its stock fell 7.77%.

NKTR class action lawsuit securities fraud clinical trial failure REZOLVE-AA trial rezpegaldesleukin enrollment protocol violations stock price decline

Sentiment note

The company is accused of materially misleading investors by overstating trial prospects and failing to disclose enrollment protocol violations. The failed clinical trial and subsequent 7.77% stock price decline further support the negative sentiment.